Flow Cytometry & Cell Sorting Shared Resource

流式细胞仪与细胞分选共享资源：综述 流式细胞仪和细胞分选(FCCS)共享资源的使命是提供霍林斯癌症 通过一个集成平台对细胞进行分类和分析，并评估临床前状态- CAL和临床实验数据以细胞特异性的方式。在阿曼达·C·拉鲁博士的领导下， FCCS提供全面的高速细胞分选服务，分析流式细胞仪和质量细胞仪，开发 新的方法，以及一个促进基础研究和翻译研究的教育平台。流式细胞仪 这些技术允许对生物过程进行快速的表型和功能分析，并分离单个 细胞，对于详细分析导致癌症发生和促进癌症的细胞类型至关重要的方法。 太夸张了。例如，癌症起始细胞的鉴定和特征，耐药肿瘤 肿瘤微环境中的细胞、免疫和其他细胞类型提供了关于如何- CER的发展为治疗干预打开了新的机会。临床试验的免疫监测 检查疗效和确定新的目标是最近的发展。FCCS为HCC成员提供 常规和复杂的流式细胞仪分析，可靠的细胞纯化，以及专家指导的教育和培训- ING在流式细胞术的方方面面。这是通过提供辅助和非辅助的流式细胞术来实现的 分析、咨询实验设计、样品制备、数据分析和数据准备，以及 接受过使用流式细胞仪技术和分析设备的实践培训。继续留在 不断发展的技术的前沿，自上次审查以来，FCC通过投资新的 设备(Fluidigm Helios CyTOF、MoFlo Astrios EQ、LSR Fortessa X-20和ZetaView NTA)和添加 通过招募卡斯滕·克里格博士提供的新专业知识，他是飞行时间质量细胞术和高维领域的专家- 局部单细胞分析，担任FCCS CyTOF运营经理。FCC是大学范围内努力的一方 推进未来癌症研究的科学目标，最近与当地的拉尔夫·H·约翰逊合作 弗吉尼亚医疗中心将购买Amny ImageStream Mark II成像细胞仪平台(将安装 2018年夏季)。该仪器提供了细胞信号，蛋白质转位，内部和外部信号的定量分析。 分化、形态、细胞-细胞相互作用、细胞周期、DNA损伤和修复、细胞死亡、自噬和鱼类-- 基于单细胞水平的分析。在本周期内，95家公司利用了FCCS共享资源- PARAL调查人员，包括所有研究计划中的60名肝细胞癌成员；并提供关键数据和见解 支持22份NCI资助的赠款申请和75份同行评审出版物的成功，包括《工作》 发表在影响较大的期刊上，如JCI、癌症发现、科学信号、科学免疫、柳叶刀、NAT 医学和自然。总之，FCCS共享资源推动、支持和提供了重要的应急- 向肝细胞癌社区提供癌症研究工具和方法。

FLOW CYTOMETRY & CELL SORTING SHARED RESOURCE: SUMMARY The mission of the Flow Cytometry & Cell Sorting (FCCS) Shared Resource is to provide the Hollings Cancer Center (HCC) research community with an integrated platform to sort and analyze cells and evaluate pre-clini- cal and clinical experimental data in a cell-specific manner. Under leadership of Amanda C. LaRue, PhD, the FCCS offers comprehensive high-speed cell sorting services, analytic flow and mass cytometry, development of new methodologies, and an educational platform to further basic and translational research. Flow cytometric techniques allow for rapid phenotypic and functional analysis of biological processes and isolation of single cells, methodologies that are critical for detailed analyses of cell types contributing to cancer initiation and pro- gression. For example, identification and characterization of cancer initiating cells, therapy-resistant tumor cells, and immune and other cell types in the tumor microenvironment have provided key insights into how can- cer evolves, opening new opportunities for therapeutic interventions. Immune monitoring for clinical trials to examine efficacy and identify new targets is a recent development. The FCCS provides HCC members with routine and complex flow cytometry analyses, reliable cell purification, and expert guided education and train- ing in all aspects of flow cytometry. This is accomplished by providing assisted and unassisted flow cytometry analysis, consultation on experimental design, sample preparation, data analysis, and data preparation, along with hands-on training in the use of flow cytometric technology and analytical equipment. To remain at the leading edge of an evolving technology, since the last review the FCCS expanded services by investing in new equipment (Fluidigm Helios CyTOF, MoFlo Astrios EQ, LSR Fortessa X-20, and ZetaView NTA) and adding novel expertise by recruiting Carsten Krieg, PhD, an expert in time-of-flight mass cytometry and high dimen- sional single cell analysis, as FCCS CyTOF Operations Manager. The FCCS is party to university-wide efforts to advance future scientific goals of cancer research, and recently partnered with the local Ralph H. Johnson VA Medical Center to purchase the Amnis ImageStream Mark II imaging cytometry platform (to be installed Summer 2018). This instrument provides quantitative analysis of cell signaling, protein translocation, internali- zation, morphology, cell-cell interaction, cell cycle, DNA damage and repair, cell death, autophagy, and FISH- based assays at the single-cell level. During the current cycle FCCS Shared Resource was utilized by 95 prin- cipal investigators, including 60 HCC members in all research programs; and provided key data and insights to support the success of 22 NCI-funded grant applications and 75 peer-reviewed publications, including work published in high-impact journals such as JCI, Cancer Discov, Sci Signal, Sci Immunol, Lancet Oncol, Nat Med, and Nature. In summary, the FCCS Shared Resource advances, supports and provides important emerg- ing cancer research tools and methodology to the HCC community.